Ivacaftor

Ivacaftor User Guide: Comprehensive Overview, Applications, Case Studies & Purchasing Information

Table of Contents

• 1. Product Specifications & Comparative Analysis
• 2. Clinical Applications & Therapeutic Use
• 3. Administration Guidelines & Best Practices
• 4. Clinical Case Studies & Patient Outcomes
• 5. Enterprise Client Implementations
• 6. Consultation & Procurement Services

1. Product Specifications & Comparative Analysis

2. Clinical Applications & Therapeutic Use

Ivacaftor demonstrates exceptional efficacy in:

• Enhancing CFTR protein function in patients with gating mutations
• Improving pulmonary function (FEV1 increase 10-15%)
• Reducing pulmonary exacerbations by 55%
• Normalizing sweat chloride levels within 2 weeks

3. Administration Guidelines & Best Practices

Optimal Administration Protocol:

1. Take with high-fat food (20-30g fat content)
2. Maintain consistent dosing schedule (±1 hour)
3. Monitor liver enzymes bi-monthly initially
4. Assess CYP3A interactions with concomitant medications

4. Clinical Case Studies & Patient Outcomes

Case Study 1: 24yo male G551D mutation

• Baseline FEV1: 58% predicted
• Week 4: FEV1 ↑14.5%
• Month 6: 62% reduction in IV antibiotics

Case Study 2: Pediatric patient R117H mutation

• Sweat chloride reduction from 98mmol/L to 42mmol/L
• BMI percentile improvement from 25th to 48th

5. Enterprise Client Implementations

University Hospital Implementation:

• 132 CF patients treated since 2019
• 78% reduction in hospital admissions
• $2.3M annual cost savings

Regional Healthcare Network:

• Implemented genetic screening protocol
• 94% mutation detection rate
• Treatment initiation within 14 days of diagnosis

6. Consultation & Procurement Services

Contact our therapeutic specialists for:

• Genetic testing coordination
• Dosage optimization strategies
• Insurance prior authorization support
• Volume purchasing agreements

Email: info@vivalr.com
Phone: (86) 15866781826

Technical Specifications Deep Dive

Ivacaftor’s pharmacokinetic profile shows:

• T_max: 4 hours post-dose
• Half-life: 12 hours (±3)
• Protein binding: 99%

Mutation-Specific Efficacy Data

Global Clinical Trial Insights

Phase III trials demonstrated:

• 26-week sustained efficacy
• 12.5% BMI improvement in pediatric cohort
• QoL score increase of 8.2 points